Current:Home > reviewsAutoimmune disease patients hit hurdles in diagnosis, costs and care -Ascend Wealth Education
Autoimmune disease patients hit hurdles in diagnosis, costs and care
Will Sage Astor View
Date:2025-04-10 19:25:05
After years of debilitating bouts of fatigue, Beth VanOrden finally thought she had an answer to her problems in 2016 when she was diagnosed with Hashimoto's disease, an autoimmune disorder.
For her and millions of other Americans, that's the most common cause of hypothyroidism, a condition in which the thyroid, a butterfly-shaped gland in the neck, doesn't produce enough of the hormones needed for the body to regulate metabolism.
There's no cure for Hashimoto's or hypothyroidism. But VanOrden, who lives in Athens, Texas, started taking levothyroxine, a much-prescribed synthetic thyroid hormone used to treat common symptoms, like fatigue, weight gain, hair loss, and sensitivity to cold.
Most patients do well on levothyroxine and their symptoms resolve. Yet for others, like VanOrden, the drug is not as effective.
For her, that meant floating from doctor to doctor, test to test, and treatment to treatment, spending about $5,000 a year.
"I look and act like a pretty energetic person," says VanOrden, 38, explaining that her symptoms are not visible. "But there is a hole in my gas tank," she says. And "stress makes the hole bigger."
Autoimmune diseases occur when the immune system mistakenly attacks and damages healthy cells and tissues. Other common examples include rheumatoid arthritis, lupus, celiac disease, and inflammatory bowel disease. There are more than 80 such diseases, affecting up to an estimated 50 million Americans, disproportionately women. Overall, the cost of treating autoimmune diseases is estimated at more than $100 billion annually in the U.S.
Despite their frequency, finding help for many autoimmune diseases can prove frustrating and expensive. Getting diagnosed can be a major hurdle because the range of symptoms looks a lot like those of other medical conditions, and there are often no definitive identifying tests, says Dr. Sam Lim, clinical director of the Division of Rheumatology at Emory University School of Medicine in Atlanta. In addition, some patients feel they have to fight to be believed, even by a clinician. And after a diagnosis, many autoimmune patients rack up big bills as they explore treatment options.
"They're often upset. Patients feel dismissed," Dr. Elizabeth McAninch, an endocrinologist and thyroid expert at Stanford University, says of some patients who come to her for help.
Insufficient medical education and lack of investment in new research are two factors that hinder overall understanding of hypothyroidism, according to Antonio Bianco, a University of Chicago endocrinologist and leading expert on the condition.
Some patients become angry when their symptoms don't respond to standard treatments, either levothyroxine or that drug in combination with another hormone, says Douglas Ross, an endocrinologist at Massachusetts General Hospital in Boston. "We will have to remain open to the possibility that we're missing something here," he says.
Jennifer Ryan, 42, says she has spent "thousands of dollars out-of-pocket" looking for answers. Doctors did not recommend thyroid hormone medication for the Huntsville, Alabama, resident — diagnosed with Hashimoto's after years of fatigue and weight gain — because her levels appeared normal. She recently switched doctors and hopes for the best.
"You don't walk around hurting all day long and have nothing wrong," Ryan says.
And health insurers typically deny coverage of novel hypothyroidism treatments, says Brittany Henderson, an endocrinologist and founder of the Charleston Thyroid Center in South Carolina, which sees patients from all 50 states. "Insurance companies want you to use the generics even though many patients don't do well with these treatments," she says.
Meanwhile, the extent of Americans' thyroid problems can be seen in drug sales. Levothyroxine is among the five most prescribed medications in the U.S. every year. Yet research points to some overprescribing of the drug for those with mild hypothyroidism.
A recent study, paid for by AbbVie — maker of Synthroid, a brand-name version of levothyroxine — said a medical and pharmacy claims database showed that the prevalence of hypothyroidism, including milder forms, rose from 9.5% of Americans in 2012 to 11.7% in 2019.
The number of people diagnosed will rise as the population ages, says McAninch. Endocrine disruptors — natural or synthetic chemicals that can affect hormones — could account for some of that increase, she says.
In their search for answers, patients sometimes connect on social media, where they ask questions and describe their thyroid hormone levels, drug regimens, and symptoms. Some online platforms offer information that's dubious at best, but overall, social media outlets have increased patients' understanding of hard-to-resolve symptoms, Bianco says.
They also offer one another encouragement.
VanOrden, who has been active on Reddit, has this advice for other patients: "Don't give up. Continue to advocate for yourself. Somewhere out there is a doctor who will listen to you." She has started an alternative treatment — desiccated thyroid medication, an option not approved by the FDA — plus a low dose of the addiction drug naltrexone, though the data is limited. She's feeling better now.
Research of autoimmune thyroid disease gets little funding, so the underlying causes of immune dysfunction are not well studied, Henderson said. The medical establishment hasn't fully recognized hard-to-treat hypothyroid patients, but increased acknowledgment of them and their symptoms would help fund research, Bianco says.
"I would like a very clear, solid acknowledgment that these patients exist," he says. "These people are real."
KFF Health News, formerly known as Kaiser Health News (KHN), is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.
veryGood! (6868)
Related
- Tom Holland's New Venture Revealed
- Climate Scientists Take Their Closest Look Yet at the Warming Impact of Aviation Emissions
- How Much Global Warming Is Fossil Fuel Infrastructure Locking In?
- Taylor Swift Totally Swallowed a Bug During Her Eras Tour Stop in Chicago
- Krispy Kreme offers a free dozen Grinch green doughnuts: When to get the deal
- Elliot Page Shares Update on Dating Life After Transition Journey
- You'll Love Ariana Grande Harder for Trolling Her Own Makeup Look
- Adding Batteries to Existing Rooftop Solar Could Qualify for 30 Percent Tax Credit
- Tarte Shape Tape Concealer Sells Once Every 4 Seconds: Get 50% Off Before It's Gone
- America's Most Wanted suspect in woman's 1984 killing returned to Florida after living for years as water board president in California
Ranking
- Juan Soto to be introduced by Mets at Citi Field after striking record $765 million, 15
- Biden Puts Climate Change at Center of Presidential Campaign, Calling Trump a ‘Climate Arsonist’
- Chrissy Teigen Believed She Had an Identical Twin After Insane DNA Test Mishap
- Read the full text of the dissents in the Supreme Court's affirmative action ruling by Sotomayor and Jackson
- US wholesale inflation accelerated in November in sign that some price pressures remain elevated
- Huge Western Fires in 1910 Changed US Wildfire Policy. Will Today’s Conflagrations Do the Same?
- Court Sides With Trump on Keystone XL Permit, but Don’t Expect Fast Progress
- How Much Global Warming Is Fossil Fuel Infrastructure Locking In?
Recommendation
Off the Grid: Sally breaks down USA TODAY's daily crossword puzzle, Triathlon
Semi-truck driver was actively using TikTok just before fiery Arizona car crash that killed 5, officials say
Cameron Boyce Honored by Descendants Co-Stars at Benefit Almost 4 Years After His Death
Florida police say they broke up drug ring selling fentanyl and xylazine
A White House order claims to end 'censorship.' What does that mean?
In Exxon Climate Fraud Case, Judge Rejects Defense Tactic that Attacked the Prosecutor
Can Massachusetts Democrats Overcome the Power of Business Lobbyists and Pass Climate Legislation?
A Kentucky Power Plant’s Demise Signals a Reckoning for Coal